The Prevention Of Postmenopausal Osteoporosis With Lasofoxifene And Cytokine Evaluation

The Effect Of Lasofoxifene On Local Mediators Of Bone Resorption In The Prevention Of Postmenopausal Osteoporosis

Status

Completed

Phases

Phase 2

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00674453

Acronym

LACE

Enrollment

Registered

2008-05-07

Start date

2004-09-30

Completion date

2007-09-30

Last updated

2011-08-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Bone Loss

Keywords

Osteoporosis, lasofoxifene, bone density, bone markers

Brief summary

The objective of the study is to demonstrate the effects that lasofoxifene has on serum markers of bone metabolism.

Interventions

DRUGLasofoxifene

Oral tablet, 0.25 mg, daily, 2 years

OTHERPlacebo

Matching placebo tablet given once daily for 2 years

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

BASIC_SCIENCE

Masking

QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender

FEMALE

Age

50 Years to No maximum

Healthy volunteers

Inclusion criteria

* Postmenopausal women over 50 years who have low bone mineral density.

Exclusion criteria

* Women who are under 50 years of age, are premenopausal, or who currently have osteoporosis are excluded.

Design outcomes

Primary

Measure	Time frame
Change in bone mineral density of the lumbar spine.	2 years

Secondary

Measure	Time frame
The secondary outcomes are the levels of cells and proteins in the blood that provide information about the health of bone, along with change in bone mineral density of the hip and forearm.	2 years

Countries

United Kingdom

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026